Mereo Biopharma Share Discussion Threads

[daveboy1] 28/2/2020 12:17

Yes, I thought so also. Mr Market having none of it, of course.

[leedslad001] 28/2/2020 12:04

Great news

[harleymaxwell] 25/2/2020 13:16

Guess what's mildly interesting is that with these perceived sells the price would have dropped quickly a few weeks back whereas now the price holds steady

[showmethemoneyhoney01] 21/2/2020 23:29

And look what happened on Nasdaq. This is only going one way. Sat on £30k worth. Could add a sizable chunk to my SIPP in the next year or two

[master rsi] 21/2/2020 15:59

Share price on the way up late on the day just like yesterday

[ny boy] 21/2/2020 14:55

All good here, I got 50p price to fill resistance level.

[showmethemoneyhoney01] 21/2/2020 11:13

This will give any newbies an overview of how advanced some of this already is.

[showmethemoneyhoney01] 21/2/2020 07:22

US close at $2.38. UK works out at 36.2p ( 2.38 divided by 5 multiplied by 0.78)

[master rsi] 20/2/2020 23:27

Today's Intraday

[master rsi] 20/2/2020 23:15

MPH has been underperforming MREO by 15% during the last 6 month

chart of MPH v MREO

[harleymaxwell] 20/2/2020 21:17

Finished up 25 % in the US.Been a painful downhill experience here's hoping we've bottomed!

[showmethemoneyhoney01] 20/2/2020 16:55

1 analyst recently given (13-2-20) MPH outperform rating with a 12 month target of 650p. Link above in Financial Times. A 20 bagger in 12 months. Patience needed but rewards could be huge.

[costax1654x] 20/2/2020 16:00

How's possible to buy cheaper?i mean....I short sell a company,and after I buy cheaper?to cover?

[bioking] 20/2/2020 15:20

DNL about to explode , Institutional investor added 1 million shares this week . LOTS of BIG NEWS around the corner =10+ BAGGER GEM RALLLYYYYYYYYYYYY

Diurnal (DNL)
Market Cap £27 M
Price: 31p



Upcoming Catalysts:

MAA-Acceptance for Chronocort in February/March 2020

Alkindi approval in Israel expected in 2Q 2020

Alkindi approval in Australien expected in 2Q 2020

US-Partnership for Alkindi & Chronocort expected in 1H 2020

Alkindi & Chronocort Partnership for Asia für Japan und China

US-Approval for Alkindi expected in 4Q 2020

EU Approval for Chronocort expected in 4Q/1Q 2020/21


Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses

[master rsi] 19/2/2020 23:51

Back in the Nasdaq the shares never went so low as here yesterday
and something more positive, they finished UP 12.3% at $1.8382 +0.2009

[master rsi] 19/2/2020 23:09

re - They should be paying a premium

Is all DEPENDS WHO IS DOING THE APROACHING
but a 20% discount after the share price at its lows is over the top.

[dave4545] 19/2/2020 14:01

Is it ?

They are paying 18.8p per share

We have to pay 24p

They should be paying a premium

[tiananmen] 19/2/2020 13:40

Excellent RNS

[ny boy] 11/2/2020 03:25

Holding many of these types of stocks, not trading as no time, too busy enjoying SE Asia, I recommend winters away from blighty, certainly a good detox, healthy eating and a low alcohol intake to start the new decade off, hopefully I can continue this when I return in the Spring.